17th Jun 2021 13:42
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 16 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,592,584 5.41 | 959,251 1.45 | ||||
(2) Derivatives (other than options) | 488,189 0.74 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 4,080,773 6.15 | 959,251 1.45 | ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase(New Borrow)
Purchase(Loan Return)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 1,800
7,700
190 1,019 5,968 600 4,159 928 11 8
2 5 7 16 5,968 186 21 6 113 41 6 17 6 40 5 9 22 16 19 2 45 10 3 94 10 31 69 11 14 28 3 | N/A
N/A
4.1700 USD 4.1680 USD 4.1647 USD 4.1633 USD 4.1607 USD 4.1600 USD 4.0500 USD 4.0300 USD
4.2000 USD 4.1900 USD 4.1700 USD 4.1669 USD 4.1647 USD 4.1600 USD 4.1529 USD 4.1500 USD 4.1400 USD 4.1306 USD 4.1300 USD 4.1282 USD 4.1233 USD 4.1220 USD 4.1200 USD 4.1100 USD 4.1000 USD 4.0925 USD 4.0900 USD 4.0850 USD 4.0836 USD 4.0800 USD 4.0700 USD 4.0650 USD 4.0600 USD 4.0545 USD 4.0538 USD 4.0500 USD 4.0414 USD 4.0300 USD 4.0200 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 5,968 | 4.1648 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 17 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma